Industry Insights

  1. C-Suite Changes Help Biotech Narrow Focus But Maintain Drive To Treat Fatal Neonatal Brain Injury 8/5/2026

    Newly-appointed leaders at ReAlta Life Sciences discuss their skill sets, their goals for advancing a therapy for hypoxic ischemic encephalopathy (HIE), and how they keep momentum as they strive to help bring this potentially lifesaving therapy to market.

  2. Accelerating Psychedelic Therapeutics: A Regulatory Inflection Point In Mental Health 8/4/2026

    A 2026 executive order is fast-tracking psychedelic therapies for depression, PTSD, and addiction. Understand what this regulatory shift means for your next clinical trial.

  3. 3 Ways To Solve Data Friction In Modern Clinical Data Management 8/4/2026

    Senior clinical data manager Shasidar Reddy Abbidi shares how to reduce data friction with targeted automation, early standards adoption, and clearer workflows that move data to decisions faster.

  4. How Visible Is Your Clinical Trial To AI? 8/3/2026

    Ross Jacksons explores how clinical trials show up — it at all — in AI tools and what that means for sponsors' approach to publicizing trial information.

  5. AI Tools In Informed Consent: What Sponsors Need To Know About Risk 8/1/2026

    AI tools carry different risks. See how they can impact participant communications, where bias and inaccuracies emerge, and why human review is critical to protecting study integrity.

  6. Configuration Over Code: Why RTSM Architecture Matters Long After Go-Live 8/1/2026

    Learn how configuration-driven RTSM architecture can simplify protocol changes, reduce operational burden, and help teams manage amendments with greater efficiency and control.

  7. Reducing Supply Risk in Cell & Gene Therapy Trials 7/31/2026

    In cell and gene therapy trials, success depends on coordination. Learn how visibility, workflow control, and alignment help reduce risk and protect patient-specific treatments.

  8. Supply Without Drag: Why Modern Supply Execution Needs a Different Kind of RTSM 7/31/2026

    Gain visibility, flexible supply management, and real-time decision support to reduce waste, control costs, and align supply with evolving trial needs.

  9. Why Amendments Break Trials and How Elosity R3 Fixes It 7/31/2026

    Protocol amendments are inevitable. The challenge is managing them without disrupting trial execution.

  10. The Expanding Role Of GLP-1 Receptor Agonists In CNS Clinical Research 7/31/2026

    Metabolic drugs show promise for brain disorders. Emerging evidence suggests they reduce addictive behaviors and may help treat neurodegenerative diseases, opening new pathways for addiction and neurological care.